Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Investigating the role of RNA-binding proteins in telomere replication stress and alternative lengthening of telomeres

Project description

Targeting telomere maintenance in cancer

Telomeres are protective caps at the ends of chromosomes that maintain genome stability. Most cancer cells maintain telomeres by reactivating an enzyme called telomerase. However, 10-15 % of cancers including aggressive types such as osteosarcoma and glioblastoma use an alternative pathway called alternative lengthening of telomeres (ALT), which maintains telomere length through a DNA repair process. This allows cancer cells to divide indefinitely. Supported by the Marie Skłodowska-Curie Actions programme, the RBPandALT project aims to investigate the role of RNA-binding proteins in regulating ALT activity. The goal is to identify RNA-binding proteins that influence telomere stability in ALT-positive cancers, characterise their mechanisms of action and evaluate their potential as therapeutic targets. Project findings could open new avenues for treating aggressive tumours.

Objective

Telomeres are protective structures at chromosome ends that prevent genome instability. In most cancer cells, telomere shortening is counteracted by telomerase reactivation. However, 10–15% of cancers, including aggressive types like osteosarcoma and glioblastoma, use a telomerase-independent pathway known as Alternative Lengthening of Telomeres (ALT). ALT relies on homology-directed DNA repair and is triggered by persistent replication stress at telomeres. Despite recent advancements in cancer therapy, ALT+ cancers currently lack targeted therapies and have a poor prognosis, highlighting the need to increase our understanding of ALT and develop new treatments against these aggressive tumours.
Increasing evidence suggests a role of RNA-binding proteins (RBPs) in DNA replication stress response and telomere stability. Therefore, I hypothesise that a subset of RBPs influence telomere replication stress and can modulate ALT activity. Towards this, I plan to:

1) Perform a CRISPR-based screen in ALT-positive and ALT-negative cancer cell lines to identify RBPs that affect telomeric replication stress and ALT activity.

2) Study how top candidate RBPs regulate telomere replication stress and ALT-specific telomere DNA synthesis using a range of molecular assays.

3) Evaluate the therapeutic potential of targeting these RBPs in ALT-positive cancers by testing their effects on cell viability and response to DNA damaging agents.

This work will reveal new RBP regulators of ALT and provide insight into the interplay between RNA metabolism, replication stress, and telomere maintenance. This project will provide a deeper, mechanistic understanding of how RNA-binding proteins influence telomere replication stress and ALT, filling a critical gap in telomere biology and paving the way for innovative cancer treatments against these aggressive tumours.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2025-PF

See all projects funded under this call

Coordinator

THE FRANCIS CRICK INSTITUTE LIMITED
Net EU contribution
€ 260 347,92
Address
1 MIDLAND ROAD
NW1 1AT London
United Kingdom
Region
London Inner London — West Camden and City of London
Activity type
Research Organisations
Links
Total cost
No data